Déjà vu for Aveo and tivozanib
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
AACR 2019 – Entinostat turns Syndax’s frown upside down
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
AACR 2019 – Chi-Med has savolitinib filing in its sights
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Events overtake Bavencio in ovarian cancer
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Imbruvica resistance provides early but fertile development ground
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
Scholar thinks Glaxo made a wise move to back Merck
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
Bristol’s doomsday scenario: could Opdivo start shrinking next year?
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
Go or no go? Johnson & Johnson awaits Spravato nod
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Asco-GU 2019 – checkpoint blockers might not be created equal after all
Until now all PD-(L)1 blockers were assumed to have broadly similar activity, with any differences being put down to trial design; the latest renal cancer data could…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.